Herpes simplex virus: Difference between revisions
From IDWiki
(created outline) |
(Initial completion of background section) |
||
| Line 1: | Line 1: | ||
* Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[Human herpesvirus]] family |
|||
* Cause typical painful vesicular lesions on labia or external genitals |
|||
* Occasionally cause a viral encephalitis |
|||
== Background == |
== Background == |
||
=== Microbiology === |
=== Microbiology === |
||
* |
* Enveloped, double-stranded DNA virus |
||
* HSV-1 and HSV-2 are morphologically and genetically distinct viruses |
|||
* Can be infected with both |
|||
=== Epidemiology === |
=== Epidemiology === |
||
* Worldwide distribution, and only found in humans |
|||
* Most common cause of genital lesions |
|||
* Spread through person-to-person contact with skin or mucosa; not spread via fomits |
|||
* HSV-1 is more common, with 90% of adults having antibodies by age 40 |
|||
** Often acquired in childhood in Asia and Africa |
|||
** More common in lower SES populations |
|||
* HSV-2 has seroprevalence of 15-20% in US |
|||
** More common in women than men, in HIV-infected people, and in MSM |
|||
** May be subclinical if already infected with HSV-1 |
|||
=== Pathophysiology === |
=== Pathophysiology === |
||
* Fusion of envelope and cell membrane is mediated by viral glycoproteins B, C, and D and host cell proteins cellular heparin sulfate, TNF receptors, and immunoglobulins |
|||
* Internal capsid is released, which makes its way to the nucleus |
|||
* Viral DNA polymerase enzyme and viral DNA helicase are targets of antivirals |
|||
* Viral DNA may remain latent in about 10% of nearby neurons, characterized by latency-associated transcripts (LATs) |
|||
** Despite being latent, virus can still be shed in mucosa anywhere from 1/10 to 3/4 of days |
|||
* HSV-1 prefers trigeminal ganglia as well as cervical ganglia, or sacral nerve root ganglia if genital |
|||
== Clinical Presentation == |
== Clinical Presentation == |
||
* Incubation period usually within 5 days for primary infection |
|||
== Diagnosis == |
== Diagnosis == |
||
Revision as of 15:32, 16 October 2019
- Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the Human herpesvirus family
- Cause typical painful vesicular lesions on labia or external genitals
- Occasionally cause a viral encephalitis
Background
Microbiology
- Enveloped, double-stranded DNA virus
- HSV-1 and HSV-2 are morphologically and genetically distinct viruses
- Can be infected with both
Epidemiology
- Worldwide distribution, and only found in humans
- Most common cause of genital lesions
- Spread through person-to-person contact with skin or mucosa; not spread via fomits
- HSV-1 is more common, with 90% of adults having antibodies by age 40
- Often acquired in childhood in Asia and Africa
- More common in lower SES populations
- HSV-2 has seroprevalence of 15-20% in US
- More common in women than men, in HIV-infected people, and in MSM
- May be subclinical if already infected with HSV-1
Pathophysiology
- Fusion of envelope and cell membrane is mediated by viral glycoproteins B, C, and D and host cell proteins cellular heparin sulfate, TNF receptors, and immunoglobulins
- Internal capsid is released, which makes its way to the nucleus
- Viral DNA polymerase enzyme and viral DNA helicase are targets of antivirals
- Viral DNA may remain latent in about 10% of nearby neurons, characterized by latency-associated transcripts (LATs)
- Despite being latent, virus can still be shed in mucosa anywhere from 1/10 to 3/4 of days
- HSV-1 prefers trigeminal ganglia as well as cervical ganglia, or sacral nerve root ganglia if genital
Clinical Presentation
- Incubation period usually within 5 days for primary infection
Diagnosis
Management
References
- a b M. Howard, J. W. Sellors, D. Jang, N. J. Robinson, M. Fearon, J. Kaczorowski, M. Chernesky. Regional Distribution of Antibodies to Herpes Simplex Virus Type 1 (HSV-1) and HSV-2 in Men and Women in Ontario, Canada. Journal of Clinical Microbiology. 2003;41(1):84-89. doi:10.1128/jcm.41.1.84-89.2003.
